PLUR · XBRL financial data

Pluri financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PLUR's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue	—	234	287	326	1,336	1,016
Cost of revenue	—	—	9	4	682	563
Gross profit	—	234	278	322	654	453
Research and development	30,533	24,605	17,413	12,446	12,851	15,092
General and administrative	20,557	17,450	11,779	10,034	9,979	10,299
Other operating income (expense)	—	—	(798)	1,680	(206)	476
Operating income (loss)	(50,623)	(41,593)	(27,246)	(22,158)	(22,176)	(24,938)
Interest income	—	—	—	1,406	1,144	488
Interest expense	78	887	843	866	873	932
Other income (expense)	—	—	(798)	1,680	(206)	476
Income tax expense (benefit)	—	—	—	—	(5)	(25)
Net income (loss)	(49,865)	(41,242)	(28,321)	(20,888)	(22,583)	(23,821)
Earnings per share, basic USD per share	(1.77)	(1.28)	(0.78)	(3.99)	(3.56)	(2.44)
Earnings per share, diluted USD per share	(1.77)	(1.28)	(0.78)	(3.99)	(3.56)	(2.44)
Weighted average shares, basic thousands of shares	28,114	32,192	36,652	5,240	6,337	9,744
Weighted average shares, diluted thousands of shares	—	32,192	36,652	5,240	6,337	9,744

Fiscal years (PLUR's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	31,241	9,772	5,360	6,783	5,895	3,529
Short-term investments	33,709	—	—	—	—	—
Accounts receivable	19	3	—	—	—	—
Prepaid and other current assets	1,824	1,724	969	868	824	810
Total current assets	67,371	57,747	41,409	31,107	22,095	8,730
Property and equipment, net	1,499	739	688	688	1,823	1,566
Right-of-use asset	728	8,270	7,633	6,558	6,900	6,164
Goodwill	—	—	—	—	3,136	3,136
Total assets	93,538	68,065	50,797	39,527	38,683	24,878
Accrued liabilities	5,941	1,630	1,209	1,223	1,178	928
Total current liabilities	11,517	6,829	5,621	4,454	32,328	32,719
Lease liability, non-current	100	6,505	5,748	5,026	6,102	6,487
Accumulated deficit	(330,021)	(371,263)	(399,584)	(420,472)	(443,055)	(466,876)
Total stockholders' equity	57,151	30,039	13,355	96	(6,842)	(23,036)
Total liabilities and equity	93,538	68,065	50,797	39,527	38,683	24,878
Common shares outstanding (cover page) thousands of shares	32,005	32,620	41,352	5,470	8,156	12,345

Fiscal years (PLUR's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	(49,865)	(41,242)	(28,321)	(20,888)	(22,583)	(23,821)
Stock-based compensation	13,968	8,909	3,977	2,618	2,143	3,726
Depreciation and amortization	—	—	—	—	316	511
Net cash from operating activities	(30,910)	(36,501)	(22,857)	(18,021)	(18,211)	(19,588)
Purchases of property and equipment	373	280	262	323	1,618	633
Net cash from investing activities	(7,265)	11,783	9,698	10,584	8,026	9,903
Proceeds from issuing common stock	36,589	—	8,024	91	9,580	5,074
Net cash from financing activities	61,402	7,500	8,024	8,841	9,533	7,038
Net change in cash	22,609	(20,425)	(5,157)	1,415	(475)	(2,620)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.